中科基本情況INTRODUCTION
 
   吉林省中科生物工程有限公司是以生物工程技術(shù)為主的科技型企業(yè)，致力于干細(xì)胞產(chǎn)品與技術(shù)在再生治療中的應(yīng)用。公司總資產(chǎn)4178萬元人民幣，占地25000平方米，建筑面積3780平方米，已按工業(yè)化標(biāo)準(zhǔn)完成全部配套工程。配有國際化現(xiàn)代化高尖端研究、科研、生產(chǎn)設(shè)備。研發(fā)團(tuán)隊(duì)擁有專業(yè)技術(shù)人員44人，均具有生物工程、生物制劑專業(yè)特長(zhǎng)，其中34人擁有生物工程及生物化學(xué)等專業(yè)碩士、博士學(xué)位。
 
   Jilin Zhongke Bio-engineering Co., Ltd. (JZB) is a leader in bio-engineering research. JZB focuses on applications of stem cells related products and technologies in regenerative therapy. With a total investment of 41.78 million RMB, it has established 3780 m2 research and production facility according to industry standards. It has 44 technicists (34 with Master Degree or Ph.D. degrees in stem cells or tissue engineering) in research.
 
 

    干細(xì)胞、組織工程、再生醫(yī)療是公司的特色項(xiàng)目。近年來，應(yīng)用干細(xì)胞對(duì)惡性腫瘤和糖尿病的治療取得了重大的突破。并成為國家衛(wèi)生部首次正式批準(zhǔn)干細(xì)胞技術(shù)在臨床應(yīng)用的單位。
 
   JZB focuses on stem cell research, tissue engineering and regenerative therapy.Thus far,JZB has made major advancements in treating cancer and diabetes using stem cell technologies. JZB got the first license from Ministry of Health of the P.R.China to carry on the stem cell technology in clinical application.